Further investigations are needed to determine whether vimentin inhibitors (51) have therapeutic effects in patients with PDAC with low PBRM1 expression, poorly differentiated PDAC, squamous molecular subtype PDAC, or undifferentiated pancreatic carcinoma. Here, VIM is linked to exocrine pancreatic carcinoma.